Haloperidol

A mixed antagonist at dopamine D2, D3, and serotonin 5-HT2A receptors (Kis = 0.14, 0.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Application Haloperidol has been used: in ethanol to serves as an inhibitor of Erg2p to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines in receptor internalization assay as an

Application Haloperidol has been used: in ethanol to serves as an inhibitor of Erg2p to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines in receptor internalization assay as an

Application Haloperidol has been used: in ethanol to serves as an inhibitor of Erg2p to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines in receptor internalization assay as an

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

A butyrophenone derivative which is used in the treatment of schizophrenia and delirium binds to the dopamine D2 receptor (Ki = 0.1 nM), antagonizing dopamine signaling.

A butyrophenone derivative which is used in the treatment of schizophrenia and delirium binds to the dopamine D2 receptor (Ki = 0.1 nM), antagonizing dopamine signaling.

HALOXON-